MII IG Kerndatensatz-Modul Molekulares Tumorboard
2026.0.0 - release
Unknown region code '276'
MII IG Kerndatensatz-Modul Molekulares Tumorboard, published by Medizininformatik-Initiative. This guide is not an authorized publication; it is the continuous build for version 2026.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/medizininformatik-initiative/kerndatensatzmodul-molekulares-tumorboard/ and changes regularly. See the Directory of published versions
{
"resourceType" : "ResearchStudy",
"id" : "mii-exa-mtb-study-cldn6",
"meta" : {
"profile" : [
🔗 "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-studie|2026.0.0"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ResearchStudy mii-exa-mtb-study-cldn6</b></p><a name=\"mii-exa-mtb-study-cldn6\"> </a><a name=\"hcmii-exa-mtb-study-cldn6\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mii-pr-mtb-studie.html\">MII PR MTB Studieversion: null2026.0.0)</a></p></div><p><b>identifier</b>: <a href=\"NamingSystem-mii-ns-mtb-nct.html\" title=\"NamingSystem für Identifikatoren des Nationalen Centrums für Tumorerkrankungen (NCT)\">MII_NS_MTB_NCT</a>/04503278</p><p><b>status</b>: Active</p><p><b>primaryPurposeType</b>: <span title=\"Codes:\">treatment</span></p><p><b>phase</b>: <span title=\"Codes:\">phase-1</span></p><p><b>condition</b>: <span title=\"Codes:{http://snomed.info/sct 369757002}\">Solid tumor configuration</span></p><p><b>keyword</b>: <span title=\"Codes:\">Non-small cell lung cancer (NSCLC)</span></p><p><b>enrollment</b>: <a href=\"Group-mii-exa-mtb-study-cldn6-eligibility-criteria.html\">Group: type = person; actual = false; quantity = 145</a></p><p><b>period</b>: 2020-09-16 --> 2040-01</p><p><b>sponsor</b>: <a href=\"Organization-mii-exa-mtb-study-sponsor-biontech.html\">Organization BioNTech Cell & Gene Therapies GmbH</a></p><p><b>principalInvestigator</b>: <a href=\"PractitionerRole-mii-exa-mtb-study-investigator-biontech.html\">PractitionerRole Study coordinator</a></p><p><b>site</b>: <a href=\"Location-mii-exa-mtb-study-cldn6-location-11.html\">Location Karolinska Comprehensive Cancer Center Cancerstudieenheten Huddinge Karolinska Universitetssjukhuset</a></p><blockquote><p><b>arm</b></p><p><b>name</b>: Part 1 - CLDN6 CAR-T: Dose escalation in lymphodepleted patients until the MTD and/or RP2D</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: Part 2 Vaccine-modulated - CLDN6 uRNA-LPX/CLDN6 modRNA-LPX: Dose escalation until the MTD and/or RP2D</p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Occurrence of treatment-emergent adverse events (TEAEs) including ≥ Grade 3, serious, fatal TEAEs by relationship</p><p><b>type</b>: <span title=\"Codes:\">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) due to TEAEs</p><p><b>type</b>: <span title=\"Codes:\">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Occurrence of dose-limiting toxicity (DLT) during the DLT evaluation period</p><p><b>type</b>: <span title=\"Codes:\">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Change from baseline in the levels and kinetics of soluble immune factors measured by cytokine multiplex assay</p><p><b>type</b>: <span title=\"Codes:\">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Objective response rate (ORR) defined as the proportion of patients in whom a complete response (CR) or partial response (PR) (per response evaluation criteria in solid tumors [RECIST 1.1]) is observed as best overall response</p><p><b>type</b>: <span title=\"Codes:\">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Disease control rate (DCR) defined as the proportion of patients in whom a CR or PR or stable disease (SD) (per RECIST 1.1, SD assessed at least 6 weeks after the first dose) is observed as best overall response</p><p><b>type</b>: <span title=\"Codes:\">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Duration of response (DOR) defined as the time from first objective response (CR or PR per RECIST 1.1) to first occurrence of objective progressive disease (PD) per RECIST 1.1/recurrence or death from any cause, whichever occurs first</p><p><b>type</b>: <span title=\"Codes:\">secondary</span></p></blockquote></div>"
},
"identifier" : [
{
"system" : "https://www.medizininformatik-initiative.de/fhir/modul-mtb/sid/nct",
"value" : "04503278"
}
],
"status" : "active",
"primaryPurposeType" : {
"coding" : [
{
"code" : "treatment"
}
]
},
"phase" : {
"coding" : [
{
"code" : "phase-1"
}
]
},
"condition" : [
{
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "369757002",
"display" : "Solid tumor configuration"
}
]
}
],
"keyword" : [
{
"text" : "Non-small cell lung cancer (NSCLC)"
}
],
"enrollment" : [
{
🔗 "reference" : "Group/mii-exa-mtb-study-cldn6-eligibility-criteria"
}
],
"period" : {
"start" : "2020-09-16",
"end" : "2040-01"
},
"sponsor" : {
🔗 "reference" : "Organization/mii-exa-mtb-study-sponsor-biontech"
},
"principalInvestigator" : {
🔗 "reference" : "PractitionerRole/mii-exa-mtb-study-investigator-biontech"
},
"site" : [
{
🔗 "reference" : "Location/mii-exa-mtb-study-cldn6-location-11"
}
],
"arm" : [
{
"name" : "Part 1 - CLDN6 CAR-T: Dose escalation in lymphodepleted patients until the MTD and/or RP2D"
},
{
"name" : "Part 2 Vaccine-modulated - CLDN6 uRNA-LPX/CLDN6 modRNA-LPX: Dose escalation until the MTD and/or RP2D"
}
],
"objective" : [
{
"name" : "Occurrence of treatment-emergent adverse events (TEAEs) including ≥ Grade 3, serious, fatal TEAEs by relationship",
"type" : {
"coding" : [
{
"code" : "primary"
}
]
}
},
{
"name" : "Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) due to TEAEs",
"type" : {
"coding" : [
{
"code" : "primary"
}
]
}
},
{
"name" : "Occurrence of dose-limiting toxicity (DLT) during the DLT evaluation period",
"type" : {
"coding" : [
{
"code" : "primary"
}
]
}
},
{
"name" : "Change from baseline in the levels and kinetics of soluble immune factors measured by cytokine multiplex assay",
"type" : {
"coding" : [
{
"code" : "secondary"
}
]
}
},
{
"name" : "Objective response rate (ORR) defined as the proportion of patients in whom a complete response (CR) or partial response (PR) (per response evaluation criteria in solid tumors [RECIST 1.1]) is observed as best overall response",
"type" : {
"coding" : [
{
"code" : "secondary"
}
]
}
},
{
"name" : "Disease control rate (DCR) defined as the proportion of patients in whom a CR or PR or stable disease (SD) (per RECIST 1.1, SD assessed at least 6 weeks after the first dose) is observed as best overall response",
"type" : {
"coding" : [
{
"code" : "secondary"
}
]
}
},
{
"name" : "Duration of response (DOR) defined as the time from first objective response (CR or PR per RECIST 1.1) to first occurrence of objective progressive disease (PD) per RECIST 1.1/recurrence or death from any cause, whichever occurs first",
"type" : {
"coding" : [
{
"code" : "secondary"
}
]
}
}
]
}